Daxor Corporation (DXR) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↑
27.96
+19% vs avg
5yr avg: 23.57
30Y Low4.0·High76.4
P/FCF
2211.41
↑+53% vs avg
5yr avg: 1449.43
30Y Low1.6·High171.9
P/B Ratio
↓
1.32
↓-36% vs avg
5yr avg: 2.07
30Y Low0.8·High3.1
ROE
↑
1.5%
↑-79% vs avg
5yr avg: 7.4%
30Y Low-47%·High31%
Debt/EBITDA
↓
0.35
↓-29% vs avg
5yr avg: 0.50
30Y Low0.2·High3.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DXR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Daxor Corporation trades at 88.6x earnings, 40% above its 5-year average of 63.3x, sitting at the 91st percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 301%. On a free-cash-flow basis, the stock trades at 2211.4x P/FCF, 53% above the 5-year average of 1449.4x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $57M | $37M | $44M | $79M | $46M | $49M | $39M | $31M | $17M | $32M | $29M |
| Enterprise Value | $58M | $38M | $45M | $80M | $48M | $49M | $41M | $35M | $20M | $32M | $31M |
| P/E Ratio → | 88.64 | 69.91 | 158.42 | 15.27 | 9.56 | — | — | — | — | 24.98 | — |
| P/S Ratio | 26.66 | 17.48 | 1.29 | — | — | — | — | — | — | 17.18 | — |
| P/B Ratio | 1.32 | 1.04 | 1.31 | 2.71 | 2.15 | 3.14 | 3.08 | 2.35 | 1.25 | 2.05 | 2.02 |
| P/FCF | 2211.41 | 1449.43 | — | — | — | — | 12.65 | — | — | 19.80 | 1.58 |
| P/OCF | 2211.41 | 1449.43 | — | — | — | — | 12.65 | — | — | 19.80 | 1.58 |
P/E links to full P/E history page with 30-year chart
DXR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Daxor Corporation's enterprise value stands at 28.0x EBITDA, 19% above its 5-year average of 23.6x. The Healthcare sector median is 14.2x, placing the stock at a 97% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 17.82 | 1.31 | — | — | — | — | — | — | 17.52 | — |
| EV / EBITDA | 27.96 | 18.45 | 54.05 | 13.07 | 8.71 | — | — | — | — | 25.96 | — |
| EV / EBIT | 92.60 | 61.10 | 137.12 | 15.21 | 10.04 | — | — | — | — | 21.91 | — |
| EV / FCF | — | 1477.84 | — | — | — | — | 13.08 | — | — | 20.19 | 1.65 |
DXR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Daxor Corporation earns an operating margin of 29.2%. Operating margins have expanded from -1485.9% to 29.2% over the past 3 years, signaling improving operational efficiency. ROE of 1.5% is modest. ROIC of 1.3% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 99.5% | 407.6% | 138.3% | 124.5% | 419.3% | 129.2% | 119.8% | 84.9% | 104.2% |
| Operating Margin | 29.2% | 29.2% | 1.0% | -1485.9% | -181.6% | 61.7% | 431.1% | 119.4% | 112.9% | 80.0% | 105.9% |
| Net Profit Margin | 25.2% | 25.2% | 0.8% | -1465.4% | -181.6% | 60.8% | 431.1% | 96.4% | 122.6% | 79.3% | 122.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.5% | 1.5% | 0.9% | 20.7% | 25.8% | -12.0% | -3.8% | -6.6% | -8.5% | 9.8% | -46.9% |
| ROA | 1.5% | 1.5% | 0.9% | 18.7% | 22.9% | -11.1% | -3.1% | -4.8% | -6.2% | 7.0% | -27.3% |
| ROIC | 1.3% | 1.3% | 0.8% | 14.7% | 18.4% | -8.8% | -2.4% | -4.8% | -5.2% | 6.9% | -19.1% |
| ROCE | 1.7% | 1.7% | 1.0% | 19.3% | 23.7% | -11.6% | -3.1% | -6.0% | -5.7% | 7.1% | -23.6% |
DXR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Daxor Corporation carries a Debt/EBITDA ratio of 0.4x, which is very conservative (89% below the sector average of 3.2x). Interest coverage of 7.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.04 | 0.14 | 0.01 | 0.11 | 0.34 | 0.32 | 0.18 | 0.27 |
| Debt / EBITDA | 0.35 | 0.35 | 0.90 | 0.20 | 0.55 | — | — | — | — | 2.26 | — |
| Net Debt / Equity | — | 0.02 | 0.02 | 0.04 | 0.11 | -0.03 | 0.11 | 0.34 | 0.24 | 0.04 | 0.10 |
| Net Debt / EBITDA | 0.35 | 0.35 | 0.90 | 0.20 | 0.42 | — | — | — | — | 0.50 | — |
| Debt / FCF | — | 28.41 | — | — | — | — | 0.43 | — | — | 0.39 | 0.08 |
| Interest Coverage | 7.30 | 7.30 | 6.72 | 72.47 | 242.19 | -205.98 | -3.45 | -9.05 | -15.65 | 39.31 | -49.06 |
DXR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.17x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.61x to 0.17x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 0.25 | 0.61 | 0.95 | — | 0.42 | 0.51 | 0.60 | 335.00 | 272.35 |
| Quick Ratio | 0.17 | 0.17 | 0.25 | 0.61 | 0.95 | — | 0.42 | 0.51 | 0.60 | 335.00 | 272.35 |
| Cash Ratio | — | — | — | — | 0.88 | 0.87 | — | — | 14.52 | 279.34 | 268.69 |
| Asset Turnover | — | 0.06 | 0.99 | -0.01 | -0.10 | -0.17 | -0.01 | -0.05 | -0.05 | 0.09 | -0.36 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 1.66 | 0.15 | -17.80 | -4.28 | -3.81 | -103.91 | -13.40 | -16.33 | 9.12 | -1.64 |
DXR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Daxor Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 1.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 0.7% | 0.4% | 0.5% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | 7.8% | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.1% | 1.4% | 0.6% | 6.6% | 10.5% | — | — | — | — | 4.0% | — |
| FCF Yield | 0.0% | 0.1% | — | — | — | — | 7.9% | — | — | 5.1% | 63.4% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 1.4% | 1.4% | 2.9% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 2.1% | 1.7% | 3.5% |
| Shares Outstanding | — | $5M | $5M | $9M | $4M | $4M | $4M | $4M | $4M | $4M | $4M |
Peer Comparison
Compare DXR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DXRYou | $57M | 88.6 | 28.0 | 2211.4 | 100.0% | 29.2% | 1.5% | 1.3% | 0.4 |
 TFX | $6B | -6.3 | 18.3 | 22.9 | 56.2% | 12.8% | -24.5% | 3.4% | 6.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 BAX | $10B | -11.4 | 27.2 | 31.8 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 BDX | $52B | 24.7 | 14.0 | 19.5 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 ISRG | $144B | 51.7 | 39.0 | 58.0 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ABT | $154B | 11.6 | 16.1 | 24.2 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 SYK | $118B | 36.6 | 21.2 | 27.5 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ZBH | $17B | 24.8 | 9.8 | 11.7 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
DXR — Frequently Asked Questions
Quick answers to the most common questions about buying DXR stock.
What is Daxor Corporation's P/E ratio?
Daxor Corporation's current P/E ratio is 88.6x. The historical average is 32.6x. This places it at the 91th percentile of its historical range.
What is Daxor Corporation's EV/EBITDA?
Daxor Corporation's current EV/EBITDA is 28.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.3x.
What is Daxor Corporation's ROE?
Daxor Corporation's return on equity (ROE) is 1.5%. The historical average is 0.1%.
Is DXR stock overvalued?
Based on historical data, Daxor Corporation is trading at a P/E of 88.6x. This is at the 91th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Daxor Corporation's profit margins?
Daxor Corporation has 100.0% gross margin and 29.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Daxor Corporation have?
Daxor Corporation's Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.